Absence of cutaneous TNFα-producing CD4+ T cells and TNFα may allow for fibrosis rather than epithelial cytotoxicity in murine sclerodermatous graft-versus-host disease, a model for human scleroderma

Journal of Investigative Dermatology

Volumn 127, Issue 8, 2007, Pages 1905-1914

  Askew, David ^a   Zhou, Lixin ^a   Wu, Cayun ^a   Chen, Guofen ^a   Gilliam, Anita C ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 2; MINOR HISTOCOMPATIBILITY ANTIGEN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE; MESSENGER RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTING CELL; APOPTOSIS; ARTICLE; CD4+ T LYMPHOCYTE; CELL INTERACTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; DISEASE ACTIVITY; FEMALE; GENETIC ANALYSIS; GRAFT VERSUS HOST REACTION; KERATINOCYTE; MALE; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCLERODERMA; SKIN EPITHELIUM; SKIN FIBROSIS; SKIN INJURY; T LYMPHOCYTE ACTIVATION; ANIMAL; CELL COMMUNICATION; DISEASE MODEL; DRUG ANTAGONISM; FIBROSIS; GENETICS; HUMAN; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; PATHOLOGY; PHYSIOLOGY; SKIN; SPLEEN; SYSTEMIC SCLEROSIS;

ANIMALS; ANTIGEN-PRESENTING CELLS; APOPTOSIS; CD4-POSITIVE T-LYMPHOCYTES; CELL COMMUNICATION; CYTOKINES; DISEASE MODELS, ANIMAL; FIBROSIS; GRAFT VS HOST DISEASE; HUMANS; KERATINOCYTES; LYMPHOCYTE ACTIVATION; MICE; RNA, MESSENGER; SCLERODERMA, SYSTEMIC; SKIN; SPLEEN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34447563995     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/sj.jid.5700813     Document Type: Article

References (42)

1. Abraham DJ, Varga J (2005) Scleroderma: from cell and molecular mechanisms to disease models. Trends Immunol 26:587-95
2. Anderson BE, McNiff JM, Jain D, Blazar BR, Shlomchik WD, Shlomchik MJ (2005) Distinct roles for donor- and host-derived antigen-presenting cells and costimulatory molecules in murine chronic graft-versus-host disease: requirements depend on target organ. Blood 105:2227-34
3. Banovic T, MacDonald KP, Morris ES, Rowe V, Kuns R, Don A et al. (2005) TGF-beta in allogeneic stem cell transplantation: friend or foe? Blood 106:2206-14
4. Browne PV, Weisdorf DJ, DeFor T, Miller WJ, Davies SM, Filipovich A et al. (2000) Response to thalidomide therapy in refractory chronic graft-versus-host disease. Bone Marrow Transplant 26:865-9
5. Chizzolini C, Parel Y, De Luca C, Tyndall A, Akesson A, Scheja A et al. (2003) Systemic sclerosis Th2 cells inhibit collagen production by dermal fibroblasts via membrane-associated tumor necrosis factor alpha. Arthritis Rheum 48:2593-604
6. Couriel D, Saliba R, Hicks K, Ippoliti C, de Lima M, Hosing C et al. (2004) Tumor necrosis factor-alpha blockade for the treatment of acute GVHD. Blood 104:649-54
7. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB et al. (2002) Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 8:793-800
8. Dong H, Zhu G, Tamada K, Chen L (1999) B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med 5:1365-9
9. Duffner UA, Maeda Y, Cooke KR, Reddy P, Ordemann R, Liu C et al. (2004) Host dendritic cells alone are sufficient to initiate acute graft-versus-host disease. J Immunol 172:7393-8
10. Ferrara JL, Cooke KR, Pan L, Krenger W (1996) The immunopathophysiology of acute graft-versus-host-disease. Stem Cells 14:473-89
11. Ferrara JL, Levy R, Chao NJ (1999) Pathophysiologic mechanisms of acute graft-vs. host disease. Biol Blood Marrow Transplant 5:347-56
12. Gilliam AC, Whitaker-Menezes D, Korngold R, Murphy GF (1996) Apoptosis is the predominant form of epithelial target cell injury in acute experimental graft-versus-host disease. J Invest Dermatol 107:377-83
13. Ichiki Y, Bowlus CL, Shimoda S, Ishibashi H, Vierling JM, Gershwin ME (2006) T cell immunity and graft-versus-host disease (GVHD). Autoimmun Rev 5:1-9
14. Ishida Y, Kondo T, Takayasu T, Iwakura Y, Mukaida N (2004) The essential involvement of cross-talk between IFN-gamma and TGF-beta in the skin wound-healing process. J Immunol 172:1848-55
15. Kaplan DH, Anderson BE, McNiff JM, Jain D, Shlomchik MJ, Shlomchik WD (2004) Target antigens determine graft-versus-host disease phenotype. J Immunol 173:5467-75
16. Kataoka Y, Iwasaki T, Kuroiwa T, Seto Y, Iwata N, Hashimoto N et al. (2001) The role of donor T cells for target organ injuries in acute and chronic graft-versus-host disease. Immunology 103:310-8
17. Korngold R, Marini JC, de Baca ME, Murphy GF, Giles-Komar J (2003) Role of tumor necrosis factor-alpha in graft-versus-host disease and graft-versus-leukemia responses. Biol Blood Marrow Transplant 9:292-303
18. Mavalia C, Scaletti C, Romagnani P, Carossino AM, Pignone A, Emmi L et al. (1997) Type 2-helper T-cell predominance and high CD30 expression in systemic sclerosis. Am J Pathol 151:1751-8
19. McCormick LL, Zhang Y, Tootell E, Gilliam AC (1999) Anti-TGF-beta treatment prevents skin and lung fibrosis in murine sclerodermatous graft-versus-host disease: a model for human scleroderma. J Immunol 163:5693-9
20. Merad M, Hoffmann P, Ranheim E, Slaymaker S, Manz MG, Lira SA et al. (2004) Depletion of host Langerhans cells before transplantation of donor alloreactive T cells prevents skin graft-versus-host disease. Nat Med 10:510-7
21. Mori R, Kondo T, Ohshima T, Ishida Y, Mukaida N (2002) Accelerated wound healing in tumor necrosis factor receptor p55-deficient mice with reduced leukocyte infiltration. FASEB J 16:963-74
22. Nakanishi K, Yoshimoto T, Tsutsui H, Okamura H (2001) Interleukin-18 regulates both Th1 and Th2 responses. Annu Rev Immunol 19:423-74
23. Oliver SJ, Moreira A, Kaplan G (2000) Immune stimulation in scleroderma patients treated with thalidomide. Clin Immunol 97:109-20
24. Remberger M, Jaksch M, Uzunel M, Mattsson J (2003) Serum levels of cytokines correlate to donor chimerism and acute graft-vs. host disease after haematopoietic stem cell transplantation. Eur J Haematol 70:384-91
25. Rothstein DM, Sayegh MH (2003) T-cell costimulatory pathways in allograft rejection and tolerance. Immunol Rev 196:85-108
26. Rottoli P, Magi B, Perari MG, Liberatori S, Nikiforakis N, Bargagli E et al. (2005) Cytokine profile and proteome analysis in bronchoalveolar lavage of patients with sarcoidosis, pulmonary fibrosis associated with systemic sclerosis and idiopathic pulmonary fibrosis. Proteomics 5:1423-30
27. Scala E, Pallotta S, Frezzolini A, Abeni D, Barbieri C, Sampogna F et al. (2004) Cytokine and chemokine levels in systemic sclerosis: relationship with cutaneous and internal organ involvement. Clin Exp Immunol 138:540-6
28. Schiller M, Javelaud D, Mauviel A (2004) TGF-beta-induced SMAD signaling and gene regulation: consequences for extracellular matrix remodeling and wound healing. J Dermatol Sci 35:83-92
29. Schmaltz C, Alpdogan O, Muriglan SJ, Kappel BJ, Rotolo JA, Ricchetti ET et al. (2003) Donor T cell-derived TNF is required for graft-versus-host disease and graft-versus-tumor activity after bone marrow transplantation. Blood 101:2440-5
30. Shustov A, Nguyen P, Finkelman F, Elkon KB, Via CS (1998) Differential expression of Fas and Fas ligand in acute and chronic graft-versus-host disease: up-regulation of Fas and Fas ligand requires CD8+ T cell activation and IFN-gamma production. J Immunol 161:2848-55
31. Tsutsui H, Yoshimoto T, Hayashi N, Mizutani H, Nakanishi K (2004) Induction of allergic inflammation by interleukin-18 in experimental animal models. Immunol Rev 202:115-38
32. Valentini G, Baroni A, Esposito K, Naclerio C, Buommino E, Farzati A et al. (2001) Peripheral blood T lymphocytes from systemic sclerosis patients show both Th1 and Th2 activation. J Clin Immunol 21:210-7
33. Visentainer JE, Lieber SR, Persoli LB, Vigorito AC, Aranha FJ, de Brito Eid KA et al. (2003) Serum cytokine levels and acute graft-versus-host disease after HLA-identical hematopoietic stem cell transplantation. Exp Hematol 31:1044-50
34. Vogelsang GB, Lee L, Bensen-Kennedy DM (2003) Pathogenesis and treatment of graft-versus-host disease after bone marrow transplant. Annu Rev Med 54:29-52
35. Yamane K, Ihn H, Asano Y, Jinnin M, Tamaki K (2003) Antagonistic effects of TNF-alpha on TGF-beta signaling through down-regulation of TGF-beta receptor type II in human dermal fibroblasts. J Immunol 171:3855-62
36. Yoo YH, Gilliam AC, Whitaker-Menezes D, Korngold R, Murphy GF (1997) Experimental induction and ultrastructural characterization of apoptosis in murine acute cutaneous graft-versus-host disease. Arch Dermatol Res 289:389-98
37. Young V, Ho M, Vosper H, Belch JJ, Palmer CN (2002) Elevated expression of the genes encoding TNF-alpha and thromboxane synthase in leucocytes from patients with systemic sclerosis. Rheumatology (Oxford) 41:869-75
38. Yu J, Wei M, Becknell B, Trotta R, Liu S, Boyd Z et al. (2006) Pro- and antiinflammatory cytokine signaling: reciprocal antagonism regulates interferon-gamma production by human natural killer cells. Immunity 24:575-90
39. Zhang Y, McCormick LL, Gilliam AC (2003) Latency-associated peptide prevents skin fibrosis in murine sclerodermatous graft-versus-host disease, a model for human scleroderma. J Invest Dermatol 121:713-9
40. Zhang Y, McCormick LL, Desai SR, Wu C, Gilliam AC (2002a) Murine sclerodermatous graft-versus-host disease, a model for human scleroderma: cutaneous cytokines, chemokines, and immune cell activation. J Immunol 168:3088-98
41. Zhang Y, Shlomchik WD, Joe G, Louboutin JP, Zhu J, Rivera A et al. (2002b) APCs in the liver and spleen recruit activated allogeneic CD8+ T cells to elicit hepatic graft-versus-host disease. J Immunol 169:7111-8
42. Zhou L, Askew D, Wu C, Chen G, Gilliam AC (2007) Cutaneous gene expression by DNA microarray in murine sclerodermatous graft versus host disease, a model for human scleroderma. J Invest Dermatol 127:281-92